Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo controlled, crossover, ascending single dose safety tolerability, pharmacokinetic and pharmacodynamic study of Neu-120 in patients with advanced phase idiopathic Parkinson's Disease with levodopa induced dyskinesia.

Next Previous
X
Search
Trial Profile

A double-blind, placebo controlled, crossover, ascending single dose safety tolerability, pharmacokinetic and pharmacodynamic study of Neu-120 in patients with advanced phase idiopathic Parkinson's Disease with levodopa induced dyskinesia.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neu 120 (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors NEURIM Pharmaceuticals

    • Most Recent Events

    • 08 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Apr 2014 Planned End Date changed from 1 Aug 2012 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Planned end date changed from 1 Aug 2008 to 1 Aug 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top